ArticleMelanoma research2020

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.

Linda Vidarsdottir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.